前列腺癌免疫治疗的研究进展

Research Progresss of Immunotherapy in Prostate Cancer

前列腺癌的治疗已经进入了肿瘤免疫治疗的时代，其中Sipuleucd—T已经用于症状轻微的激素抵抗前列腺癌患者的治疗。其他用于前列腺癌治疗的还有免疫检查点抑制剂（Ipilimumab）、树突状细胞疫苗（DCVax）以及肿瘤抗原（GVAX0和PROSTVAC—VF）等，均在早期临床试验中显示出乐观的应用前景，并均已进入临床Ⅲ期研究。因此，前列腺癌的免疫治疗是可行的、有效的，值得进一步探索和研究。

The treatment approach of prostate eancer has already entered the era of immunotherapy. Sipuleucel-T is the first immunotherapeutie drug for the treatment of light-symptomatic castrate-resistant pros- tate cancer. The other immunological therapeutics under clinical development are immune checkpoint inhibitor （Ipilimumab） ,dendritic cell vaccines（DCVax） ,and tumor vaccine （ GVAX and PROSTVAC-VF） ,which have shown promising potential in early phase clinical studies ,and have entered phase III clinical study. Immunotherapy for prostate cancer is feasible and effective ,woahy of further exploration and development.